The Alpha-1 Project is specifically seeking the following types of projects for focusing our initial investments:

• Anti-elastase
• Small molecules/chaperones
• Gene/stem cell therapies
• Devices for detection, monitoring, or treatment

Additional details on the full therapeutic strategies for The Alpha-1 Project can be found in the Therapeutic Strategies section.

The Alpha-1 Project seeks partnerships with individual donors, patients, academia, pharmaceutical and biotechnology companies to eliminate the effects of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1 Antitrypsin Deficiency (Alpha-1). We believe that by building upon our significant internal scientific resources, leveraging our partnerships and utilizing our unique, venture capital-like approach to evaluating and making targeted investments we will speed the development of new drug therapies and devices to combat this condition. If you are interested in discussing a research partnership with The Alpha-1 Project, please contact info@thealpha-1project.com or Jean-Marc Quach at jmquach@thealpha-1project.com or 888-920-0002. A letter of interest and an executed confidentiality agreement will be required prior to discussions.

The Alpha-1 Project will provide matching funds to pharmaceutical and biotechnology companies with highly promising compounds and devices that have the ability to eradicate the effects of liver disease and COPD caused by Alpha-1.

For more information on how you can make a donation directly to The Alpha-1 Project, contact:

Jean-Marc Quach – President and CEO
The Alpha-1 Project
3300 Ponce de Leon Boulevard
Coral Gables, Florida 33134
Phone: 305-648-9541
Toll-free: 888-920-0002
Email: jmquach@thealpha-1project.com